Effect of Nutritional Supplement Alpha-ketoglutarate for Age-related Ocular Disease
NCT ID: NCT07269704
Last Updated: 2025-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
17 participants
INTERVENTIONAL
2023-08-15
2025-06-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Determine how the eye absorbs supplements taken orally.
2. Look for specific signs in the proteins and substances in the eyes of people with eye diseases who are also taking nutritional supplements.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention of Myopia of Prematurity by Calcium Supplementation
NCT00892476
Supplementation With a Highly-Concentrated Docosahexaenoic Acid (DHA) Triglyceride in Patients With Keratoconus
NCT05756062
Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas
NCT03029104
The Effects of Low Concentration Atropine on Pupil Size and Accommodation
NCT02870478
Monthly Replacement Orthokeratology for Myopia Control in Existing Lens Wearers
NCT04295707
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Calcium alpha-ketoglutarate (Ca-aKG)
At the first and second cataract surgery of the participant, a small amount of tissue (eye fluid \~0.1 ml or 1-2 drops) is removed for analysis. Beginning one week (7 days) prior to their second cataract extraction surgery, the patient takes an oral nutritional supplement (calcium alpha-ketoglutarate) 2 times a day.
Calcium alpha-ketoglutarate
Participants took 2 g/day of calcium alpha-ketoglutarate orally, twice daily, for 7 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Calcium alpha-ketoglutarate
Participants took 2 g/day of calcium alpha-ketoglutarate orally, twice daily, for 7 days.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Able to attend all study visits and complete the study procedures
3. Women of child-bearing potential must have a negative pregnancy test within 2 weeks before cataract surgery. A pregnancy test is not required for postmenopausal women (defined as being at least 12 consecutive months without menses) or those surgically sterilized (those having a bilateral tubal ligation/bilateral salpingectomy, bilateral tubal occlusive procedure, hysterectomy, or bilateral oophorectomy).
Exclusion Criteria
2. History of supplement allergy or planned major surgery
3. Received any other clinical trial drug within 4 months
4. Calculated creatinine clearance of less than 30 ml/min
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vinit Mahajan
Professor of Ophthalmology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vinit Mahajan, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Byers Eye Institute
Palo Alto, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Filip RS, Pierzynowski SG, Lindegard B, Wernerman J, Haratym-Maj A, Podgurniak M. Alpha-ketoglutarate decreases serum levels of C-terminal cross-linking telopeptide of type I collagen (CTX) in postmenopausal women with osteopenia: six-month study. Int J Vitam Nutr Res. 2007 Mar;77(2):89-97. doi: 10.1024/0300-9831.77.2.89.
Riedel E, Nundel M, Hampl H. alpha-Ketoglutarate application in hemodialysis patients improves amino acid metabolism. Nephron. 1996;74(2):261-5. doi: 10.1159/000189319.
Wert KJ, Velez G, Kanchustambham VL, Shankar V, Evans LP, Sengillo JD, Zare RN, Bassuk AG, Tsang SH, Mahajan VB. Metabolite therapy guided by liquid biopsy proteomics delays retinal neurodegeneration. EBioMedicine. 2020 Feb;52:102636. doi: 10.1016/j.ebiom.2020.102636. Epub 2020 Feb 3.
Hou XW, Wang Y, Pan CW. Metabolomics in Age-Related Macular Degeneration: A Systematic Review. Invest Ophthalmol Vis Sci. 2020 Dec 1;61(14):13. doi: 10.1167/iovs.61.14.13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
68157
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.